Axonics, Inc. (AXNX)
After hours:
| Previous close | 66.57 |
| Open | 66.50 |
| Bid | 47.74 x 200 |
| Ask | 85.33 x 200 |
| Day's range | 66.39 - 67.09 |
| 52-week range | 47.59 - 69.68 |
| Volume | |
| Avg. volume | 861,967 |
| Market cap | 3.412B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Axonics Reports First Quarter 2024 Financial Results
IRVINE, Calif., April 30, 2024--Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2024.
- PR Newswire
Boston Scientific Announces Results for First Quarter 2024
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $495 million or $0.33 per share (EPS), compared to $300 million or $0.21 per share a year ago, and achieved adjusted3 EPS of $0.56 for
- Business Wire
Axonics Stockholders Approve Merger Agreement with Boston Scientific
IRVINE, Calif., March 22, 2024--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics’ merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results from the special meeting of stockholders held earlier today, a majority of the shares of Axonics’ common stock outstanding and entitled to vote at the special meeting voted in favor of adopting the merger agreement. Final voting results, as tabulated by an independen
